What Does the Published Research Say About NAD+?

What This Article Covers

This article summarizes published research on NAD+ for technical review. It separates direct human evidence, review-level context, and animal or mechanistic work so the reader can see what has actually been tested before seeing the limitations.

The supplied NAD⁺ literature set spans isolated human trials, multiple reviews, and extensive preclinical/mechanistic work focused largely on nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Review and mechanistic papers dominate; direct primary human evidence is sparse and narrowly scoped. The evidence set explicitly cautions that mechanistic plausibility does not establish clinical utility and that broad anti-aging claims are unsupported by the available human data [pubmed:24786309][pubmed:37424179].

Bottom Line

• Most published NAD⁺ research in this evidence set is review or preclinical. Direct human evidence exists but is narrow and endpoint-specific [pubmed:37619764][pubmed:29249689][pubmed:35499054][pubmed:37424179].
• One randomized, double-blind, placebo-controlled NMN trial evaluated NAD⁺ metabolism biomarkers and arterial stiffness in a defined population; findings on those endpoints should not be generalized to broad anti-aging or disease-modifying efficacy [pubmed:36797393].
• Dosing parameters and long-term, generalized safety in humans remain incompletely defined in the literature set [pubmed:35499054][pubmed:37068054].

Human Evidence (Direct)

• A randomized, double-blind, placebo-controlled trial assessed the effects of long-term NMN on NAD⁺ metabolism and arterial stiffness. The endpoints and population are specific, and results should not be extrapolated to other outcomes or groups [pubmed:36797393].
• The evidence set’s clinical claims emphasize that while some human data exist, conclusions must remain anchored to the studied population and endpoints rather than generalized beyond them [pubmed:37619764][pubmed:24786309][pubmed:29249689][pubmed:35499054][pubmed:37424179].

Review Literature (Context, Not Primary Evidence)

These sources synthesize existing data but do not add new primary human outcomes:

• NMN-focused clinical trial updates on safety and anti-aging framing (review-level synthesis) [pubmed:37619764].
• Human-focused overview of NAD⁺-boosting compounds (mixed NMN/NR context, future directions noted) [pubmed:37068054].
• NR-specific review of what is known from human supplementation studies [pubmed:37478182].
• Benefit/risk analysis of NAD⁺ therapy in age-related disorders (conceptual framework) [pubmed:31917996].
• NMN as an anti-aging product: promises and safety concerns (review and commentary) [pubmed:35499054].

Note: Where reviews focus on NMN (e.g., [pubmed:37619764][pubmed:35499054]) versus NR (e.g., [pubmed:37478182]), conclusions should not be cross-extrapolated between compounds without direct supporting data.

Preclinical and Mechanistic Evidence

The evidence set includes mechanistic and non-human work on:

• NAD⁺ and sirtuin biology in aging and disease [pubmed:24786309][pubmed:30355082].
• The biology and potential of NAD⁺ intermediates NMN and NR [pubmed:29249689].
• In vivo evidence for NAD⁺-boosting molecules in non-human models [pubmed:29514064].
• Roles of NAD metabolism in senescence regulation and aging [pubmed:37424179].
• Potential mechanisms underlying NMN’s actions in aging contexts [pubmed:37548938].

Mechanistic plausibility and non-human in vivo findings do not establish clinical efficacy in humans [pubmed:24786309][pubmed:37424179].

What Is Not Established

• Generalized anti-aging or disease-modifying efficacy in humans is not supported by the evidence set’s evidence base [pubmed:37619764][pubmed:37424179].
• Cross-compound generalization between NMN and NR lacks direct human support when specific endpoints/populations differ [pubmed:37478182][pubmed:37619764][pubmed:35499054].
• Dosing guidance and long-term, generalized safety remain incompletely defined in humans; the literature advises caution against off-label extrapolation [pubmed:35499054][pubmed:37068054].

What Was Tested in Humans?

No controlled human intervention data were identified in the available evidence set used for this draft. That does not mean the compound has no research interest; it means human outcome claims should not be made from this article’s source base.

What Did Animal and Mechanistic Studies Show?

The available evidence set should be interpreted carefully when it includes animal, cellular, formulation, or mechanistic findings. Those findings can explain why researchers study the compound, but they should not be presented as established human outcomes.

How the Evidence Fits Together

The practical reading for NAD+ is evidence hierarchy. Human studies, when present, carry the most weight, but only for the exact population, route, comparator, and endpoint studied. Reviews can help map the field, and animal or mechanistic studies can explain biological plausibility, but neither should be used to leap beyond the human evidence.

What Is Not Established

• Broad human efficacy for NAD+ is not established by this article.
• Animal, cellular, or review-level findings should not be converted into human-use claims.
• Dosing, administration, treatment, diagnostic, or veterinary-use guidance is outside the scope of KRL materials.

Research-Use Boundary

This article summarizes published research and regulatory-source discussion for technical review. It is not medical advice, not a dosing guide, and not a recommendation for human or veterinary use. KRL materials are sold for research use only and are not for diagnostic, therapeutic, or administration purposes.

Selected Sources

• [pubmed:36797393] Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. https://pubmed.ncbi.nlm.nih.gov/36797393/
• [pubmed:37619764] The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. https://pubmed.ncbi.nlm.nih.gov/37619764/
• [pubmed:24786309] NAD+ and sirtuins in aging and disease. https://pubmed.ncbi.nlm.nih.gov/24786309/
• [pubmed:29249689] NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NR. https://pubmed.ncbi.nlm.nih.gov/29249689/
• [pubmed:35499054] Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns. https://pubmed.ncbi.nlm.nih.gov/35499054/
• [pubmed:37424179] NAD metabolism: Role in senescence regulation and aging. https://pubmed.ncbi.nlm.nih.gov/37424179/
• [pubmed:29514064] Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. https://pubmed.ncbi.nlm.nih.gov/29514064/
• [pubmed:37068054] Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions. https://pubmed.ncbi.nlm.nih.gov/37068054/
• [pubmed:37548938] Role and Potential Mechanisms of Nicotinamide Mononucleotide in Aging. https://pubmed.ncbi.nlm.nih.gov/37548938/
• [pubmed:37478182] What is really known about the effects of nicotinamide riboside supplementation in humans. https://pubmed.ncbi.nlm.nih.gov/37478182/
• [pubmed:31917996] NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis. https://pubmed.ncbi.nlm.nih.gov/31917996/
• [pubmed:30355082] Sirtuins and NAD(+) in the Development and Treatment of Metabolic and Cardiovascular Diseases. https://pubmed.ncbi.nlm.nih.gov/30355082/

Related KRL Resources

• Research Compound Catalog
• Technical Products
• FAQ